Viewing Study NCT07326566

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:15 PM
Ignite Modification Date: 2026-06-02 @ 11:45 AM
Study NCT ID: NCT07326566
Status: RECRUITING
Last Update Posted: 2026-03-19
First Post: 2026-01-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Sponsor: Black Diamond Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Glioblastoma (GBM) View
None Newly Diagnosed Glioblastoma View
None GBM View
None Glioblastoma Multiforme (GBM) View
None Glioma View
None Central Nervous System Diseases View
None Brain Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None EGFR View
None Glioblastoma View
None Unmethylated View
None Unmethylated MGMT promoter View
None Newly Diagnosed View
None temozolomide View
None Temodar View
None silevertinib View
None BDTX-1535 View
None EGFR alterations View
None epidermal growth factor receptor View
None EGFRvIII View
None epidermal growth factor receptor (EGFR) View